1IY0 Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Monopar Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.85 |
| 52 Week High | US$7.25 |
| 52 Week Low | US$1.20 |
| Beta | 1.1 |
| 11 Month Change | 0% |
| 3 Month Change | -13.95% |
| 1 Year Change | 3.93% |
| 33 Year Change | -91.40% |
| 5 Year Change | n/a |
| Change since IPO | -96.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1IY0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 0.2% |
| 1Y | 3.9% | -17.2% | 8.5% |
Return vs Industry: 1IY0 exceeded the German Biotechs industry which returned -16.1% over the past year.
Return vs Market: 1IY0 underperformed the German Market which returned 12.9% over the past year.
Price Volatility
| 1IY0 volatility | |
|---|---|
| 1IY0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 1IY0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 1IY0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Chandler Robinson | www.monopartx.com |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.
Monopar Therapeutics Inc. Fundamentals Summary
| 1IY0 fundamental statistics | |
|---|---|
| Market cap | €80.99m |
| Earnings (TTM) | -€6.04m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.4x
P/E RatioIs 1IY0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1IY0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.47m |
| Earnings | -US$6.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1IY0 perform over the long term?
See historical performance and comparison